Outlook Therapeutics News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

08.07.24	Outlook Therapeutics Says UK MHRA Grants Marketing Authorization For LYTENAVA To Treat Wet AMD (RTTNews)
08.07.24	Outlook Therapeutics® Announces UK MHRA Marketing Authorization of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD (GlobeNewswire)
01.04.24	Insiders Buying Outlook Therapeutics And 2 Other Stocks (Benzinga)
22.03.24	Why Is Eye Disease-Focused Outlook Therapeutics Stock Trading Higher On Friday? (Benzinga)
22.03.24	Outlook Therapeutics Receives Positive CHMP Opinion For ONS-5010 To Treat Wet AMD (RTTNews)
02.01.24	OTLK FINAL DEADLINE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Outlook Therapeutics, Inc. Investors to Secure Counsel Before Important January 2 Deadline in Securities Class Action - OTLK (PR Newswire)
26.12.23	ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Outlook Therapeutics, Inc. Investors With Losses to Secure Counsel Before Important January 2 Deadline in Securities Class Action - OTLK (PR Newswire)
19.12.23	Outlook Therapeutics Submits SPA For Required Study Of ONS-5010 (RTTNews)
17.12.23	ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Outlook Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - OTLK (PR Newswire)
11.12.23	ROSEN, A RANKED AND LEADING FIRM, Encourages Outlook Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - OTLK (PR Newswire)
03.12.23	ROSEN, NATIONAL TRIAL LAWYERS, Encourages Outlook Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - OTLK (PR Newswire)
28.11.23	SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Outlook Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 2, 2024 - (NASDAQ: OTLK) (PR Newswire)
27.11.23	CLASS ACTION REMINDER: Berger Montague Advises Outlook Therapeutics, Inc. (NASDAQ: OTLK) Investors to Inquire About a Securities Fraud Lawsuit by January 2, 2024 (PR Newswire)
27.11.23	Outlook Therapeutics Announces Receipt Of Type A Meeting Official Minutes On ONS-5010 BLA (RTTNews)
27.11.23	SHAREHOLDER ALERT: The Law Offices of Vincent Wong Remind Outlook Investors of a Lead Plaintiff Deadline of January 2, 2024 (PR Newswire)
26.11.23	ROSEN, NATIONAL TRIAL COUNSEL, Encourages Outlook Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - OTLK (PR Newswire)
21.11.23	SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Outlook Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 2, 2024 - (NASDAQ: OTLK) (PR Newswire)
20.11.23	SHAREHOLDER ALERT: The Law Offices of Vincent Wong Remind Outlook Investors of a Lead Plaintiff Deadline of January 2, 2024 (PR Newswire)
18.11.23	ROSEN, LEADING INVESTOR COUNSEL, Encourages Outlook Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - OTLK (PR Newswire)
16.11.23	SHAREHOLDER ALERT: Levi & Korsinsky Notifies Outlook Therapeutics, Inc.(OTLK) Investors of a Class Action Lawsuit and Upcoming Deadline (PR Newswire)
14.11.23	SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Outlook Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 2, 2024 - (NASDAQ: OTLK) (PR Newswire)
13.11.23	ATTENTION NASDAQ: OTLK INVESTORS: Contact Berger Montague About an Outlook Therapeutics, Inc. Class Action Lawsuit (PR Newswire)
11.11.23	ROSEN, AN INVESTOR RIGHTS LAW FIRM, Encourages Outlook Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - OTLK (PR Newswire)
30.08.23	Outlook Therapeutics: FDA Issues CRL For ONS-5010 BLA For Treatment Of Wet AMD (RTTNews)
23.12.22	Outlook Therapeutics Announces $25 Mln Of Registered Direct Offering At $0.87/shr (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Sonova Hldg	311.10	2.34 %	K V
Part Grp Hldg	1’249.50	1.75 %	K V
Geberit	523.00	1.24 %	K V
Novartis	92.68	1.22 %	K V
Lonza Grp	526.80	1.00 %	K V
CieFinRichemont	117.70	0.04 %	K V
Zurich Insur Gr	547.20	-0.07 %	K V
Swiss Life Hldg	726.40	-0.11 %	K V
UBS Group	28.10	-0.14 %	K V
Kuehne+Nagel Int	207.30	-0.34 %	K V

Nachrichten zu Outlook Therapeutics Inc Registered Shs

Aktien Top/Flop

Meistgelesene Nachrichten